Supplementary Materials

Supplementary Material for:

Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD)

Stephen P. Fink, Mai Yamauchi, Reiko Nishihara,* Seungyoun Jung, Aya Kuchiba, Kana Wu, Eunyoung Cho, Edward Giovannucci, Charles S. Fuchs, Shuji Ogino, Sanford D. Markowitz,* Andrew T. Chan*

*Corresponding author. E-mail: rnishiha@hsph.harvard.edu (R.N.); sxm10@cwru.edu (S.D.M.); achan@mgh.harvard.edu (A.T.C.)

Published 23 April 2014, Sci. Transl. Med. 6, 233re2 (2014)
DOI: 10.1126/scitranslmed.3008481

This PDF file includes:

  • Methods
    Table S1. Characteristics at diagnosis according to HPGD (15-PGDH) mRNA expression.
  • Table S2. Number of aspirin tablets and incident colorectal cancer grouped by HPGD (15-PGDH) mRNA expression.
  • Table S3. Duration of regular aspirin use and incident colorectal cancer grouped by HPGD (15-PGDH) mRNA expression.
  • Table S4. Regular aspirin use and incident colorectal cancer grouped by HPGD (15-PGDH) mRNA expression.
  • Table S5. Comparison of the top four most stable transcripts by program.

[Download PDF]